Immunohistochemical Expression of Ki-67 in Malignant Salivary Glands Tumors

  • Sultan Muhammad Wahid Department of Dental Surgery, PGMI/LGH Lahore
  • Faiz Rasul Department of Oral Pathology, de’Montmorency College of Dentistry, Lahore
  • Zainab Rizvi Department of Oral Pathology, de’Montmorency College of Dentistry, Lahore
  • Khurram Nadeem Lahore Medical & Dental College, Lahore
  • Ahmed Sultan CMH Medical and Dental College, Lahore
  • Muhammad Talha Haseeb Sheikh Zaid Hospital, Lahore
Keywords: Malignant salivary gland tumors (MSGTs), Mucoepidermoid carcinoma (MEC), Acinic cell carcinoma (ACC), Adenoid cystic carcinoma (ADCC), and Polymorphous low grade adenocarcinoma (PLGA).

Abstract

Objective: To determine expression of Ki-67 in MSGTs to evaluate its role in diagnosis of salivary gland tumors (SGTs).

Methodology: Sixty 60 cases of MSGTs were collected from de’Montmorency college of Dentistry, Lahore from period January, 2020 to December, 2021. Ethical permission was taken from institutional review board (DCD No.). The histopathological diagnosis and grading of MSGTs was made by H&E staining. On immunohistochemistry Labeling Index (LI) of Ki-67 was determined. Descriptive statistics were calculated on SPSS 22.

Results: Mean age of subjects was 51.1 ± 16.70 years. Adenoid Cystic Carcinoma (ADCC) is the commonest type of MSGT followed by Mucoepidermoid Carcinoma (MEC), and Acinic Cell Carcinoma (ACC) contrary to the worldwide literature where MEC exceeds ADCC. ADCC is mostly located on palate but its preferential site, in our setup, comes out to be parotid gland followed by buccal mucosa and then palate. In MSGTs, 16.7% were weak positive, 33.3% moderately positive and 50% strongly positive for Ki-67. There was a very highly significant association (P < 0.0001) between tumor-type and Ki-67 LI.

Conclusion: It is concluded that 50 % MSGTs expressed Ki-67 strong positive so is a sensitive indicator of malignancy in salivary gland tumors.

Keywords: Malignant salivary gland tumors (MSGTs), Mucoepidermoid carcinoma (MEC), Acinic cell carcinoma (ACC), Adenoid cystic carcinoma (ADCC), and Polymorphous low-grade adenocarcinoma (PLGA).

Published
2024-04-18
Section
Original Articles